What a Fungus-Specific Enzyme Reveals About Drug Discovery

Most peptide researchers work with compounds that already exist in some standardized form. But behind every reagent on your shelf, someone had to discover it first. The research on Candida albicans Rtt109 offers a window into how new targets get identified, how enzymes get characterized, and what it actually means to find an inhibitor that works. This matters because the same logic applies to any compound you're trying to understand at the bench.

What Is Rtt109, Actually?

Rtt109 is a histone acetyltransferase, which is a type of enzyme that adds an acetyl group (a small chemical tag) to histone proteins. Histones are the spools around which DNA winds inside cell nuclei. When you tag a histone with acetyl, it changes how tightly the DNA is packed, which turns genes on or off.

Here's what makes Rtt109 special: it's found only in fungi. Humans have histone acetyltransferases, but none of them are exactly like Rtt109. That fungus-specific quality is exactly why researchers care about it. If you can block Rtt109, you might be able to stop a fungal pathogen without harming the human host.

The specific target is H3K56 acetylation. That's a precise spot on the histone H3 protein (the 56th amino acid from the start, which is a lysine, hence K56). This modification matters for DNA replication and repair, and in Candida albicans specifically, it affects virulence, meaning how dangerous the fungus is.

The Chaperone Problem

When researchers tried to study Rtt109 in isolation, something odd happened: the enzyme barely worked. It needed a partner protein called Vps75 to do anything meaningful. This is a chaperone, a protein that helps other proteins fold or stay in the right shape.

The study used a "coupled HAT assay" to measure activity. They gave the enzyme a 20-amino-acid piece of histone H3 (the N-terminal tail), added acetyl-CoA (the molecule that donates the acetyl group), and measured whether acetylation happened. With Vps75 present, the reaction worked. With another chaperone called Asf1, it didn't.

Biolayer interferometry and gel filtration studies confirmed why. Rtt109 and Vps75 form a high-affinity stable complex. They stick together tightly and stay together. Asf1 doesn't form that kind of stable pairing. The practical takeaway: when you're working with enzymes that require cofactors or partner proteins, don't assume isolation equals activity. The context matters.

The research also identified a specific region of Rtt109 that's required for activity: a flexible loop spanning residues 118-160. Delete or disrupt that loop, and the enzyme loses function even if Vps75 is present. This kind of detail matters for drug design because loops often represent drug-binding sites.

Finding an Inhibitor

The researchers screened 1.35 million compounds from Life Chemicals Databases using computational docking. This is essentially a filtering process: predict which molecules might physically fit into the Rtt109 active site before ever touching a pipette.

Six candidates were tested using biolayer interferometry. The best binder was a compound called F2368-0266. Then came the key experiment: steady-state enzyme kinetics. They measured how fast the reaction proceeded at different substrate concentrations, with and without the inhibitor.

The result: F2368-0266 is a competitive inhibitor of the peptide substrate. That means it binds to the same spot where the histone peptide would attach, physically blocking the real substrate from getting in. It does NOT compete with acetyl-CoA. This is a meaningful distinction. A competitive inhibitor against the peptide suggests the drug design should focus on blocking the peptide-binding pocket, not the acetyl-CoA binding site.

For researchers thinking about inhibition at the bench, this illustrates a fundamental concept: knowing WHERE a compound binds tells you how it will behave at different concentrations. Competitive inhibitors can be overcome with enough substrate. Non-competitive inhibitors cannot.

What This Means for the Bigger Picture

Because Rtt109 affects hyphal morphogenesis (the fungus's ability to switch from round yeast form to elongated invasive form) and GPI biosynthesis (a pathway for anchoring proteins to the cell wall), blocking it could make Candida albicans less infectious. That's the clinical implication the authors mention.

The research also validates something practical: in silico screening followed by BLI validation is a viable workflow for finding enzyme inhibitors. The numbers bear this out. Out of 1.35 million candidates, six were tested experimentally, and one worked. That's inefficient by some standards, but it's how early-stage drug discovery often works.

Understanding the Rtt109-Vps75 system also teaches something broader about enzyme mechanics. Many proteins don't act alone. The assumption that your target is a single molecule can lead you astray. When you're characterizing a new peptide or protein reagent, knowing its partners, cofactors, and optimal conditions isn't academic overhead. It's the difference between a working assay and a failed one.

If you're sourcing recombinant proteins or peptides for research, the Rtt109 story is a reminder that purity and correct folding matter, but so does context. The right buffer, the right partners, the right temperature. What works in theory doesn't always work on the bench.

Frequently asked questions

What does Rtt109 do in fungi?

Rtt109 is a fungus-specific enzyme that acetylates histone H3 at lysine 56, affecting gene regulation, DNA repair, and fungal virulence.

Why does Rtt109 need Vps75 to work?

Vps75 forms a high-affinity stable complex with Rtt109 that properly positions the enzyme's active site; without it, Rtt109 has almost no activity.

What kind of inhibitor is F2368-0266?

It's a competitive inhibitor that binds the peptide substrate pocket, blocking histone peptide access but not affecting acetyl-CoA binding.

Prompted by this coverage at bioRxiv →

Related from our lab: the pen · cartridges · bacteriostatic water · reconstitution calculators

Shared by PreppinPeppers for research, educational, and demonstration awareness only. We link to third-party coverage; we do not endorse it, and nothing here is medical advice or a recommendation to use any substance in humans or animals. Our products are sold for laboratory research use only.

What the research community gets wrong about Candida albicans Rtt109

Rtt109 shows up in a lot of assay planning conversations, and a few ideas about it get repeated more often than they get checked. Here is what tends to trip people up at the bench.

• "Fungus-specific" does not mean it looks nothing like a human enzyme. Rtt109 has almost no sequence similarity to human acetyltransferases, but structural work has shown its catalytic fold is a surprise match for the metazoan p300/CBP acetyltransferase domain. If you design a binding experiment assuming the pocket is totally unlike anything characterized before, you may be ignoring useful prior structural data.
• "Chaperone-dependent" does not mean any chaperone will do. Rtt109 pairs with Vps75 to form a stable, high-affinity complex, and that pairing is what supports strong activity in vitro. Asf1 is also a histone chaperone, but it does not substitute in the same assay. Treating the two as interchangeable is a common setup mistake.
• A docking hit is not an inhibitor yet. Screening a large compound library and getting a predicted binder tells you where to look next, not what actually happens in the tube. Binding still has to be measured (for example by biolayer interferometry) and the effect on the reaction still has to be measured by enzyme kinetics before a compound earns the label.
• "Competitive inhibitor" is not a grade of strength. It describes where the compound binds, in this case the peptide substrate pocket rather than the acetyl-CoA site. It does not by itself say the compound is weak or strong. It does predict behavior: adding more substrate can outcompete a competitive inhibitor, which matters when you pick concentrations for a plate.
• H3K56 acetylation is not just generic "loosening" of DNA packing. In the literature this specific mark is tied to newly made histones during S-phase and to genome stability and repair, not to a vague on or off switch. Describing it only as opening chromatin skips the part of the biology that makes it an interesting target.

From our bench: If you run a coupled HAT assay with recombinant Rtt109 and Vps75, we want your real numbers on complex stability over a working day. Set up your reaction, then record how activity tracks with a fresh enzyme aliquot versus one held on ice or through a freeze-thaw cycle, and note the buffer, temperature, and protein source you used. Send us the raw side-by-side so other researchers can compare handling conditions. No modeled values, just what your plate reader actually showed.

Sources

1. Bacteriostatic Water for Injection, USP , FDA/DailyMed label (0.9% benzyl alcohol)
2. Duerkop et al., Biotechnol J 2018 , Impact of Cavitation, High Shear Stress and Air/Liquid Interfaces on Protein Aggregation
3. Sigma-Aldrich (Merck) , Handling and Storage Guidelines for Peptides and Proteins
4. UniProt Q5AAJ8 - Histone acetyltransferase RTT109, Candida albicans (strain SC5314)
5. Albaugh BN, Kolonko EM, Denu JM. Kinetic mechanism of the Rtt109-Vps75 histone acetyltransferase-chaperone complex. Biochemistry. 2010;49(30):6375-85. PMID 20560668
6. Tang Y, et al. Fungal Rtt109 histone acetyltransferase is an unexpected structural homolog of metazoan p300/CBP. Nat Struct Mol Biol. 2008;15(7):738-45. PMID 18568037